- Home
- OCUL
as 09-05-2025 4:00pm EST
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.8B | IPO Year: | 2014 |
| Target Price: | $17.20 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.79 - $13.82 | Next Earning Date: | 08-05-2025 |
| Revenue: | $56,664,000 | Revenue Growth: | -7.26% |
| Revenue Growth (this year): | -12.18% | Revenue Growth (next year): | 18.87% |
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Notman Donald | OCUL | See Remarks | Sep 2 '25 | Sell | $12.43 | 1,066 | $13,250.38 | 308,807 | |
| Nayak Sanjay | OCUL | Chief Strategy Officer | Aug 25 '25 | Sell | $12.04 | 1,885 | $22,695.40 | 279,738 | |
| Dugel Pravin | OCUL | See Remarks | Aug 25 '25 | Sell | $12.04 | 21,494 | $258,787.76 | 3,227,244 | |
| Kaiser Peter | OCUL | Chief Development Officer | Aug 25 '25 | Sell | $12.04 | 3,011 | $36,252.44 | 204,093 | |
| Heier Jeffrey S. | OCUL | Chief Scientific Officer | Aug 25 '25 | Sell | $12.04 | 3,063 | $36,878.52 | 259,911 |
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Zacks
2 months ago
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Simply Wall St.
3 months ago
Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years
GlobeNewswire
3 months ago
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
MT Newswires
3 months ago
Sector Update: Health Care
MT Newswires
3 months ago
Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion
GlobeNewswire
3 months ago
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
GlobeNewswire
4 months ago
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
Compare OCUL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.